FDA Rejects Optune Mya Brain Metastases PMA With Not Approvable Letter
NVCR sits 42% above its 52-week low of $9.82.
Summary
The FDA issued a Not Approvable Letter for Novocure's Optune Mya PMA in brain metastases from non-small cell lung cancer, citing uncertainty over clinical benefit rather than safety. Novocure will meet the agency to explore a path to approval without additional clinical studies, with no assurance of success.
Updates
· Dow Jones Newswires — Novocure shares fell 2.4% to $12.96 in premarket trading after the FDA rejection.
Key Events · Product Development and Regulatory · NVCR
-
FDA Issues Not Approvable Letter
The FDA declined to approve the Optune Mya PMA application for adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation.
-
Benefit Uncertainty, Not Safety
The agency's stated reason was uncertainty around the degree of clinical benefit; it did not raise concerns about Optune Mya's safety profile.
-
No Assurance on Path Forward
Novocure plans to meet the FDA to determine whether approval is possible without additional clinical studies, and cautions there is no assurance those discussions or future submissions lead to approval.
-
Setback Against a Growing Base
The decision removes a near-term indication expansion while the core business reported Q3 2026 revenue of $193.4M, up 16%, with adjusted EBITDA of $15.7M.
Analysis · NVCR · Industrial Applications And Services
Novocure's Optune Mya application for brain metastases from non-small cell lung cancer will not be approved as filed. The FDA's objection is not safety — it is that the degree of clinical benefit is too uncertain to support approval. That distinction matters: the safety profile is intact, so the path back is a data and endpoint argument rather than a product defect. Novocure says it will meet the FDA to see whether approval is possible without new clinical studies, but it explicitly warns there is no assurance those talks or any resubmission lead to approval. The brain metastases indication was one of the incremental growth opportunities layered on top of the existing glioblastoma, pancreatic and mesothelioma franchises, so this removes a near-term revenue expansion rather than impairing the commercial base — which just posted 16% revenue growth to $193.4M in Q3 with adjusted EBITDA of $15.7M.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVCR was trading at $13.95 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $9.82 to $21.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.